

Longevity Biotech 2025 Announces Partnership with the Alliance for Longevity Initiatives (A4LI)

Boston, MA – September 2025 – Longevity Biotech 2025, the premier international conference dedicated to advancing the science and business of longevity therapeutics, is proud to announce it will run **in association with the Alliance for Longevity Initiatives (A4LI)**.

Taking place on **October 22–23, 2025 in Boston**, Longevity Biotech 2025 will convene leaders from biotech, pharma, investment, and policy to explore the next wave of innovations in aging research and therapeutic development.

A4LI, the leading nonprofit dedicated to advancing government policies that improve the health and well-being of people as they age, will bring its policy expertise and advocacy perspective to the meeting. Together, Longevity Biotech 2025 and A4LI will ensure the conference not only covers cutting-edge science and translational progress but also the critical policy frameworks needed to bring longevity therapeutics from the lab to patients.

A4LI President Dylan Livingston will also join a regulatory panel discussion at Longevity Biotech 2025, bringing a policy and advocacy perspective to discussions on how to advance longevity therapeutics through evolving regulatory frameworks.

The program features presentations from leading researchers including **Dr. Paul Ridker (Harvard Medical School, Brigham and Women's Hospital)** and **Dr. Andrea Maier (National University of Singapore)**, alongside talks on the biology of aging, biomarker development, clinical translation, regulatory and investment strategies. A start-up pitch showcase will also highlight emerging ventures driving the field forward.

For more information and registration details, visit <https://www.longevity-biotech.com/>

About Longevity Biotech:

Longevity Biotech 2025 is the premier conference uniting leaders from biotech, pharma, academia, and venture capital to accelerate the development of longevity therapeutics. This forum provides a platform for collaboration and knowledge exchange, bringing together biotechnology innovators, investors, and translational researchers to address the field's unique challenges, and its promise in extending human healthspan. The event takes place October 22–23 in Boston, MA at the Wightman Mansion.

Longevity Biotech contact:

Daniel Quinn

Program Director

e-mail: dan@microbiometimes.com